Phase I-Dose Escalation to Determine MTD, Safety [clinicaltrials_resource:362cedd603df2fa63e0a37ff8848a639]

Phase I-Dose Escalation to Determine MTD, Safety [clinicaltrials_resource:362cedd603df2fa63e0a37ff8848a639]

Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:362cedd603df2fa63e0a37ff8848a639
Phase I (PH I) Mad Refractory Solid Tumor Study [clinicaltrials:NCT00099606]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Phase I-Dose Escalation to Determine MTD, Safety [clinicaltrials_resource:362cedd603df2fa63e0a37ff8848a639]

Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:362cedd603df2fa63e0a37ff8848a639
Bio2RDF identifier
362cedd603df2fa63e0a37ff8848a639
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:362cedd603df2fa63e0a37ff8848a639
measure [clinicaltrials_vocabulary:measure]
Phase I-Dose Escalation to Determine MTD, Safety
description
Tablets, Oral, Dose Finding St ...... disease progression or death.
identifier
clinicaltrials_resource:362cedd603df2fa63e0a37ff8848a639
title
Phase I-Dose Escalation to Determine MTD, Safety
@en
inDataset
type
label
Phase I-Dose Escalation to Det ...... cedd603df2fa63e0a37ff8848a639]
@en